India vs Sint Maarten (Dutch part): Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
India
0.2%
in 2024
Sint Maarten (Dutch part)
0.2%
in 2024
India rank
98th
Sint Maarten (Dutch part) rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- India
- Sint Maarten (Dutch part)
How they compare
India currently reports 0.2% against 0.2% in Sint Maarten (Dutch part), a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was India ahead.
India ranks 98th and Sint Maarten (Dutch part) ranks 98th of 246 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Sint Maarten (Dutch part) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.4% | 0.3% | 0.1% | India |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, India or Sint Maarten (Dutch part)?
- India, at 0.2% against 0.2% in Sint Maarten (Dutch part) as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between India and Sint Maarten (Dutch part)?
- 0.0%, with India ahead.
- How many years of comparable data are there for India and Sint Maarten (Dutch part)?
- 10 years are reported by both, from 2015 to 2024.
- How do India and Sint Maarten (Dutch part) rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- India ranks 98th and Sint Maarten (Dutch part) ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.